A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective
- 56 Downloads
There is a lack of comprehensive cost information for cardiovascular events since 2013.
A systematic review on the contemporary cost of cardiovascular events was therefore undertaken.
Methods complied with those recommended by the Cochrane Collaboration and the Centre for Reviews and Dissemination. Studies were unrestricted by language, were from 2013 to 23 December 2017, and included cost-of-illness data in adults with the following cardiovascular conditions: myocardial infarction (MI), stroke, transient ischaemic attack (TIA), heart failure (HF), unstable angina (UA), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or peripheral artery disease (PAD). Seven electronic databases were searched, namely Embase (Ovid), MEDLINE (Ovid), MEDLINE In-Process Citations and Daily Update (Ovid), NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) database, Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed. The included studies reported data from a variety of years (sometimes prior to 2013), so costs were inflated and converted to $US, year 2018 values, for standardization.
After de-duplication, 29,945 titles and abstracts and then 403 full papers were screened; 82 studies (88 papers) were extracted. Year 1 average cost ranges were as follows: MI ($11,970 in Sweden to $61,864 in the USA), stroke ($10,162 in Spain to $46,162 in the USA), TIA ($6049 in Sweden to $25,306 in the USA), HF ($4456 in China to $49,427 in the USA), UA ($11,237 in Sweden to $31,860 in the USA), PCI ($17,923 in Italy to $45,533 in the USA), CABG ($17,972 in the UK to $76,279 in the USA). One Swedish study reported PAD costs in a format convertible to $US, 2018 values, with a mean annual cost of $15,565.
There was considerable unexplained variation in contemporary costs for all major cardiovascular events. One emerging theme was that average costs in the USA were considerably higher than anywhere else.
The authors acknowledge the help of the following contributors who assisted with screening, data extraction, and/or quality assessment: Regina Leadley, Sonia Garcia Gonzalez-Moral, Frank O’Neill (formerly Amgen Inc.), and Anna Bychenkova (Amgen Inc.). Medical writing support was provided by Cathryn M. Carter (Amgen Inc.).
All of the listed authors conform to the requirements of the International Committee for Medical Journal Editors (ICMJE). SR, C-YW, SD, and NA designed the study, carried out the methodological framework, collected the data, reviewed the studies, and completed quality assessment. LS assisted in designing the study, developed and performed the original literature searches, and contributed to the writing and revision of the manuscript. SR, C-YW, and NA contributed to the writing, interpretation of the results, and revision of the manuscript. YQ, PR, JK, and KF participated in the study design, supervised the overall progress, and contributed to the interpretation of the results and revision of the manuscript. All authors read and approved the final manuscript. SR is the overall guarantor of this work.
Compliance with Ethical Standards
This study was funded by Amgen Inc. (Thousand Oaks, CA, USA).
Conflict of interest
Steve Ryder, Lisa Stirk, Nigel Armstrong, Ching-Yun Wei, and Sohan Deshpande are employees of Kleijnen Systematic Reviews (KSR) Ltd., an independent research company that was paid by Amgen Inc. to carry out this work. Jos Kleijnen is the owner of KSR Ltd. Pratik Rane and Yi Qian are employees and stock holders of Amgen Inc. Kathleen Fox serves as a consultant for Amgen Inc.
Human and animal rights
This manuscript reports on secondary research and does not directly report research on human participants and/or animals.
Informed consent and ethical approval were not required.
- 1.World Health Organization. Cardiovascular diseases (CVDs). Fact sheet [Internet]. World Health Organization, 2016. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 11 Nov 2016.
- 2.Khavjou O, Phelps D, Leib A. Projections of cardiovascular disease prevalence and costs: 2015–2035. Technical report [Internet]. Research Triangle Park, NC: RTI International, 2016. https://healthmetrics.heart.org/projections-of-cardiovascular-disease/. Accessed 22 Jan 2019.
- 3.Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European cardiovascular disease statistics 2017 [Internet]. Brussels: European Heart Network, 2017. http://www.ehnheart.org/component/downloads/downloads/2452. Accessed 7 Mar 2017.
- 6.Wei CY, Quek RG, Villa G, Gandra SR, Forbes CA, Ryder S, et al. A systematic review of cardiovascular outcomes-based cost-effectiveness analyses of lipid-lowering therapies. Pharmacoeconomics. 2016;27:27.Google Scholar
- 7.Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;10:10.Google Scholar
- 9.Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions [Internet]. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011. http://handbook.cochrane.org/. Accessed 23 Mar 2011.
- 10.Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care [Internet]. York: University of York, 2009. http://www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm. Accessed 23 Mar 2011.
- 12.Bank of England. Inflation calculator. 2017. http://www.bankofengland.co.uk/education/Pages/resources/inflationtools/calculator/default.aspx. Accessed 3 Mar 2017.
- 13.Fxtop.com. Inflation calculator. 2017. http://fxtop.com/en/inflationcalculator.php. Accessed 3 Mar 2017.
- 14.Exchange Rates UK. US Dollar Exchange Rate. 2017. http://www.exchangeates.org.uk/US-Dollar-USD-currency-table.html. Accessed 3 Mar 2017.
- 24.Stafylas P, Parissis J, Aletras V, Mavrodi A, Chatzopoulos S, Tsarouhas K, et al. Distribution and predictors of direct costs of acute heart failure in Greece: a social security system perspective. Eur Heart J. 2015;36:1112–3.Google Scholar
- 29.Lucioni C, Mazzi S, Rossi E, Rielli R, Calabria S, Maggioni AP. Therapeutic strategies and health costs of patients admitted for a cardiovascular event in Italy. Glob Reg Health Technol Assess. 2016;3(2):80–91.Google Scholar
- 34.Czech M, Opolski G, Zdrojewski T, Dubiel JS, Wizner B, Bolisega D, et al. The costs of heart failure in Poland from the public payer’s perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013;71(3):224–32.CrossRefPubMedGoogle Scholar
- 37.de Andres-Nogales F, Vivancos Mora J, Barriga Hernandez FJ, Diaz Otero F, Izquierdo Esteban L, Ortega-Casarrubios MA, et al. Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: the CODICE Study. Neurologia. 2015;30(9):536–44.CrossRefPubMedGoogle Scholar
- 41.Hallberg S, Gandra SR, Fox KM, Mesterton J, Banefelt J, Johansson G, et al. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data. Eur J Health Econ. 2016;17(5):591–601.CrossRefPubMedGoogle Scholar
- 45.Hasvold P, Nordanstig J, Kragsterman B, Kristensen T, Falkenberg M, Johansson S, et al. Long-term cardiovascular outcome, use of resources, and healthcare costs in patients with peripheral artery disease: results from a nationwide Swedish study. Eur Heart J Qual Care Clin Outcomes. 2018;4(1):10–17.CrossRefPubMedGoogle Scholar
- 50.Walker S, Asaria M, Manca A, Palmer S, Gale CP, Shah AD, et al. Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). Eur Heart J Qual Care Clin Outcomes. 2016;2(2):125–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Gu Q, Ma J, Li N, Yuan SW. Analysis of hospital expenditure and influencing factors of patients with acute myocardial infarction. Shanghai Jiao Tong Da Xue Xue Bao Yi Xue Ban. 2013;33(6):746–50.Google Scholar
- 57.Liu WW, Yang J, Yuan SW, Wei FQ, Ma J. Evaluation of hospitalization expense of patients with acute myocardial infarction before and after implementation of single disease quality control. Shanghai Jiao Tong Da Xue Xue Bao Yi Xue Ban. 2015;35(6):876–80.Google Scholar
- 64.Murata K, Hinotsu S, Sadamasa N, Yoshida K, Yamagata S, Asari S, et al. Healthcare resource utilization and clinical outcomes associated with acute care and inpatient rehabilitation of stroke patients in Japan. Int J Qual Health Care J Int Soc Qual Health Care. 2017;29(1):26–31.Google Scholar
- 73.Bagai A, Cantor WJ, Tan M, Tong W, Lamy A, Fitchett D, et al. Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study. Am Heart J. 2013;165(4):630–637.e2.CrossRefPubMedGoogle Scholar
- 84.Kazi DS, Ben-Yehuda O, Bonafede M, Hernandez JB, Machacz SF, Hlatky MA. Economic burden of angina and chest pain following percutaneous coronary intervention: a real-world analysis of multi-payer US claims. Circulation. 2014;130(Suppl 2):A16951.Google Scholar
- 90.Simpson AN, Bonilha HS, Kazley AS, Zoller JS, Ellis C. Marginal costing methods highlight the contributing cost of comorbid conditions in medicare patients: a quasi-experimental case-control study of ischemic stroke costs. Cost Eff Resour Alloc. 2013;11(1):29.CrossRefPubMedPubMedCentralGoogle Scholar
- 93.Yang E, Stokes M, Johansson S, Mellstrom C, Magnuson E, Cohen DJ, et al. Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. Cardiovasc Ther. 2016;26:26.Google Scholar
- 96.Da Silva G, Colosimo FC, Sousa AG, Piotto RF, Castilho V. Coronary artery bypass graft surgery cost coverage by the Brazilian Unified health system (SUS). Rev Bras Cir Cardiovasc. 2017;32(4):253–9.Google Scholar
- 106.Ali AN, Abdelhafiz A. Clinical and economic implications of AF related stroke. J Atr Fibrillation. 2016;8(5):85–92.Google Scholar
- 107.de Pouvourville G. Cost of ischemic stroke management in France (French). Arch Cardiovasc Dis Suppl. 2016;8(2):161–8.Google Scholar
- 109.Gray AM, Murphy J, Altman DG, Benedetto U, Campbell H, Flather M, et al. One-year costs of bilateral or single internal mammary grafts in the arterial revascularisation trial. Heart (British Cardiac Society). 2017;103(21):1719–26.Google Scholar